INTRODUCTION AND OBJECTIVES: Von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome with poor survival. The current recommendations have proposed uniform surveillance strategies for all patients, which neglected the obvious inter and intra familial phenotypic varieties. In this study, we aim to confirm the phenotypic heterogeneity in VHL disease and the underlying mechanism.
INTRODUCTION AND OBJECTIVES: Von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome with poor survival. The current recommendations have proposed uniform surveillance strategies for all patients, which neglected the obvious inter and intra familial phenotypic varieties. In this study, we aim to confirm the phenotypic heterogeneity in VHL disease and the underlying mechanism.
METHODS: A total of 151 parent-child pairs were enrolled for genetic anticipation analysis, and 77 sibling pairs for birth order effect analysis. Four statistical methods were used to compare the onset age of patients among different generations and different birth orders.
RESULTS: The average onset age was 18.9 years earlier in children than that in their parents, which was statistically significant in paired t test (p<0.001), RY1 (p<0.05), RY2 (p<0.01) and CPH model (p<0.001). Furthermore, the first-born siblings were affected 8.3 years later than the other ones among the maternal patients. Telomere shortening was confirmed to be associated with genetic anticipation in VHL families, while it failed to explain the birth order effect. Moreover, no significant difference was observed for overall survival between parents and children (p[0.834) and between the first-born patients and the other siblings (p[0.390) .
CONCLUSIONS: This study provides definite evidence and possible mechanisms of intra-familiar phenotypic heterogeneity in VHL families, which is helpful to the update of surveillance guidelines.
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MP14-16 DYNAMIC EVALUATION OF THE MODIFIED GLASGOW PROGNOSTIC SCALE IN PATIENTS WITH LOW RISK CLEAR CELL RENAL CELL CARCINOMA
INTRODUCTION AND OBJECTIVES:
The inflammation-based modified Glasgow Prognostic Score (mGPS) is widely used as a prognostic indicator before surgery; however, little information is available on its benefit in postoperative patients with regards to its relative change from initial preoperative value. We evaluated the usefulness of the mGPS change from before to after surgery as a prognostic factor in patients with low risk localized clear cell renal cell carcinoma (ccRCC).
METHODS: We retrospectively identified patients who underwent nephrectomy for ccRCC with preoperative mGPS[0 from 2005 to 2018. Patients with pathologic T4 or metastatic disease were excluded. Preoperative mGPS was determined within 60 days prior to surgery, and postoperative mGPS at 1 year after surgery. Change from preoperative to postoperative mGPS was assessed for association with overall or recurrence free survival. Kaplan-meier curve was used to determine survival estimates. Univariable and multivariable COX proportional hazards were used to estimate hazard ratios. CONCLUSIONS: Modified Glasgow Prognostic Score (mGPS) dynamics from preoperative to postoperative is an independent and significant predictor of overall and recurrence free survival in low risk localized ccRCC. mGPS is calculated from standardized laboratory markers that can be easily and cost-effectively obtained at any time, and change over time can be used as a prognostic indicator. The classification of unclassified renal cell carcinoma (URCC) includes morphologically distinct tumors that are generally high grade with unrecognizable cell types or pure sarcomatoid histology without typical renal cell epithelial components. In recent contemporary series, this category of tumors is remarkably heterogeneous in histopathology and genetic features. The aim of our study is to compare stage-matched patient cohorts with clear cell renal cell carcinoma (ccRCC) and URCC in terms of demographics, risk of recurrence, and overall and disease-specific survival rates.
METHODS: We conducted a single institutional retrospective cohort study analyzing our renal database which captured cases between August 2001 and July 2017. Information obtained through hospital, supplemental state, and obituary records. We investigated patient demographic data, as well as rate of recurrence, and overall and disease-specific survival.
RESULTS: There were 119 cases of unclassified renal cell carcinoma between August 2001 and July 2017 or 6.15% of all cases (Table 1) . At the time of nephrectomy, 9.48% of patients had evidence of metastasis. The median length of follow up was 20 months. The overall and disease specific mortality was 35.3% and 16.4%, respectively. No statistical difference in overall or disease-specific survival was seen between stage matched patients with ccRCC and URCC (Figures 1 and 2) .
CONCLUSIONS: To our knowledge, this is the largest cohort of patients with URCC with clinical follow up. The incidence of URCC among all patients in this cohort was greater than previously reported. Patients with URCC did not have a worse overall or disease-specific survival outcomes
